Despite the passage of the Rubio-led Uyghur Forced Labor Prevention Act (UFLPA) in 2021, a recent report has revealed that two Xinjiang-based pharmaceutical entities continue to exploit American laws for profit. To uphold the UFLPA, the U.S. Food and Drug...
NOTICIAS
Últimas Noticias
ICYMI: Rubio: Cancel Trade Benefits for Offshoring
Cancel Trade Benefits for Offshoring U.S. Senator Marco Rubio (R-FL) October 31, 2024 Newsweek Last month, President Donald Trump made waves by threatening to impose a tariff on John Deere for moving production to Mexico…. [A]s I said in my own letter to John Deere...
Rubio, Scott Urge Biden-Harris Admin to Address IV Fluid Shortage
Hurricane Helene significantly damaged North Carolina’s Baxter International IV fluid manufacturing plant. Baxter is responsible for producing more than half of the country’s IV fluid supply. This closure has strained the medical community, leading to delays in...
Rubio, Franklin, Colleagues Demand Compensation for Agricultural Land
Hurricanes Helene and Milton brought high winds, flooding, and damage across Florida. The Florida Department of Agriculture and Consumer Services estimates the total crop and infrastructure losses range from $1.5 to $2.5 billion. The State of Florida has requested...
Rubio, Scott Support Seminole Tribe’s Major Disaster Request
Due to Hurricane Milton's impact on the Seminole Tribe of Florida, their communities, and property, the tribe requested a major disaster declaration to assist in their response and recovery efforts. U.S. Senators Marco Rubio (R-FL) and Rick Scott (R-FL) sent a...
Rubio Requests Investigation Into Potentially Manipulated Research on Puberty Blockers
A National Institutes of Health (NIH)-funded study failed to publish its findings on the effects of puberty blockers on children years after completing the research. The researchers are concerned their findings would justify puberty blocker bans for minors. Political...
Rubio, Warren Introduce Bill to Address U.S. Overreliance on Foreign Pharmaceuticals
Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Elizabeth Warren (D-MA) introduced the Strengthening Supply Chains for Servicemembers and Security Act to address the national security risk posed by the United States’ reliance on foreign entities for pharmaceuticals. The legislation follows a September 2021 report from the Department of Defense (DoD) Office of Inspector General (OIG) that confirmed the DoD is over-reliant on foreign made pharmaceuticals without sufficient strategies to address domestic supply chain dysfunction. The Senators successfully secured language in the National Defense Authorization Act for Fiscal Year 2021 to require an industrial capacity vulnerability study of the DoD’s dependence on foreign-made pharmaceuticals.
“The report from the Department of Defense Office of Inspector General only confirms what was made glaringly obvious during the COVID-19 pandemic: the United States remains dangerously reliant on foreign nations for its pharmaceuticals,” Rubio said. “It is unacceptable that we do not currently have a plan in place to address these supply chain issues. I’m proud to introduce this legislation to ensure that the DoD is able to reduce its reliance on nations like China for its critical pharmaceutical needs.”
“The COVID-19 pandemic has demonstrated the vulnerability of our nation’s supply chains, including of pharmaceutical products,” Warren said. “This poses a risk not only to public health but to our national security. I’m glad to lead this bill with Senator Rubio to ensure DoD takes steps to reduce its reliance on pharmaceuticals manufactured abroad and to strengthen its supply chains,” said Senator Warren.
El texto de la carta en inglés está Strengthening Supply Chains for Servicemembers and Security Act would codify the six recommendations included in the DoD OIG report to address supply chain weaknesses:
Recommendation that the Under Secretary of Defense for Acquisition and Sustainment:
- Develop and issue implementing guidance for DoD supply chain risk management for DoD material, which includes pharmaceuticals.
- Pursue Federal legislation requiring pharmaceutical manufacturers to include APIs and final drug product country of origin information of the pharmaceuticals’ lot on the pharmaceuticals’ packaging. Specifically, the legislation would require a further review of information gaps to address reliance concerns.
Recommendation that the Director of the Defense Health Agency:
- Develop and publish implementing guidance for supply chain risk management specifically for pharmaceuticals.
- Create a chartered work group to assess risks to the pharmaceutical supply chain, identify the pharmaceuticals most critical to beneficiary care at DoD MTFs, and establish policy for allocating scarce pharmaceutical resources in case of a supply disruption.
Recommendation that the Director of the Defense Logistics Agency modify DLA Instructions 5025.03 and 3110.01 to:
- Require DLA Troop Support to coordinate annually with Military Service customers to conduct responsiveness testing of the DLA’s contingency contracts for pharmaceuticals.
- Include the contract responsiveness testing results, as reported by the Military Service customers, in the Warstopper Program annual reports.